Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Ixion receives patent allowance for technology to treat oxalate-related disorders

Sep. 10, 1998

Upregulators of LDL receptor in development at Pfizer as hypocholesterolemic agents

Sep. 10, 1998

Chugai files for regulatory approval of maxacalcitol

Sep. 10, 1998

New advances in antiobesity drug therapy reported by Novartis

Sep. 10, 1998

Glaxo Wellcome describes hypoglycemic activity of PPAR ligand

Sep. 9, 1998

Novel ACAT inhibitors from DuPont Pharmaceuticals debut at ACS meeting

Sep. 9, 1998

DuPont presents XJ-304 and related compounds as ACAT inhibitors at ACS

Sep. 9, 1998

Pfizer selects GH secretagogue as development candidate

Sep. 8, 1998

Novel lipid-lowering agent presented by Wayne Hughes Institute at scientific forum

Sep. 8, 1998

Ligand reveals tissue-selective, orally active progestational compound

Sep. 8, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...